ArticleTherapeutic advances in medical oncology2025
Time to progression is a simple and robust prognostic factor for survival in relapsed or refractory diffuse large B-cell lymphoma.
Article in Therapeutic advances in medical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Relapsed or refractory (R/R) disease following frontline treatment with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) represents a significant clinical challenge in the management of diffuse large B-cell lymphoma (DLBCL). Objectives: To address unmet medical needs, comprehensive clinical data on R/R DLBCL in real-world settings are warranted. Design: A retrospective observational study including patients from a tertiary medical center and a national population-based cohort. Methods: We conducted a retrospective cohort study of R/R DLBCL, derived from 665 consecutive patients treated with R-CHOP. Furthermore, a population-based cohort from Taiwan's National Health Insurance Research Database was established for external validation. Clinical data were comprehensively analyzed using Cox proportional hazards regression to identify independent predictors of overall survival (OS) and progression-free survival (PFS). Results: A total of 231 patients were identified from the retrospective cohort. Among them, 88 (38.1%) were found to be primarily refractory to R-CHOP, while 143 (61.9%) experienced recurrent disease. When stratified by time to progression (TTP) after R-CHOP, the 2-year OS rate ranged from 35.4% in patients with TTP <12 months to 74.4% in those with TTP ⩾24 months. Patients with TTP <12 months also demonstrated lower response rates to second-line treatments and were less likely to proceed to stem cell transplantation. In multivariate analysis, TTP was identified as an independent prognostic factor for OS and PFS. The prognostic significance of TTP was further validated in an external, population-based cohort of 723 patients with R/R DLBCL. Conclusion: This real-world study provides valuable insights into R/R DLBCL outside of clinical trial settings, revealing that TTP after frontline R-CHOP is an easy-to-use and robust prognostic predictor. Patients with a TTP of less than 12 months exhibited a particularly poor prognosis under conventional treatment, highlighting the urgent need to consider novel therapeutic approaches for this high-risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.